Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page

FDA advisory committee votes against approval of rivaroxaban for acute coronary syndrome

Thursday, 24 May 2012 12:04

On 23 May, the FDA’s Cardiovascular and Renal Drugs advisory committee voted six to four, with one abstention, against the approval of the oral anticoagulant rivaroxaban (Xarelto, Bayer Healthcare/Jansen Pharmaceuticals) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome in combination with standard antiplatelet therapy (aspirin with or without clopidogrel). 

Data from the pivotal phase 3 ATLAS ACS 2 TIMI 51 (Anti-Xa therapy to lower cardiovascular events in addition to aspirin with/without thienopyridine therapy in subjects with acute coronary syndrome) supported rivaroxaban’s new indication. Results from the study showed that rivaroxaban given in combination with standard antiplatelet therapy were superior to standard therapy alone in preventing secondary cardiovascular events in patients with acute coronary syndrome. There were also low rates of major bleeding events in coronary artery bypass graft (CABG) surgery. Despite these results, the FDA’s panel voted against based on missing data on early patient withdrawals.

The FDA assigned a priority review designation to the supplemental new drug application filed on 29 December 2011 for rivaroxaban in patients with acute coronary syndrome. Recommendations from the advisory committee will be considered by the FDA in its review, but the FDA is not required to follow them.

Rivaroxaban is currently approved in the USA to reduce the risk of blood clots in the legs and lungs of people who have just had knee or hip replacement surgery, and to reduce the risk of both haemorrhagic and thrombotic strokes as well as other blood clots in people with atrial fibrillation not caused by a heart valve problem.

Add New Comment

Related Items

Most popular

Friday, 29 Jul 2016
Miguel Haime (VA Boston Healthcare System and Boston Medical Center, Boston, USA) is to present an abstract about Somhulation’s DuraGraft during a rapid response session at the 2016 annual meeting of ... Oral abstract on DuraGraft to be presented at EACTS


TAVI durability: A rose by any other name is still a rose
Wednesday, 20 Jul 2016
The data that Dvir presented at EuroPCR, as reported by Cardiovascular News, indicate that there is a significant increase in valve degeneration between five and seven years after a transcatheter ... TAVI durability: A rose by any other name is still a rose

Exploring the borders of TAVI
Monday, 11 Jul 2016
The NOTION 2 trial, which recently enrolled a 64-year-old female with Society of Thoracic Surgeon (STS) score 1.2% as its first patient, is comparing the use of TAVI with the use of surgical aortic ... Exploring the borders of TAVI


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions